Sign In
Buy RGEN
$149.78
+2.72 (+1.85%)
At Close: Aug 04, 2026
Repligen (RGEN) Lags Q2 Earnings Estimates
09:46am, Tuesday, 29'th Jul 2025
Repligen (RGEN) came out with quarterly earnings of $0.37 per share, missing the Zacks Consensus Estimate of $0.4 per share. This compares to earnings of $0.33 per share a year ago.
Repligen Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance
07:30am, Tuesday, 29'th Jul 2025
WALTHAM, Mass., July 29, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its s
Here's Why Repligen (RGEN) is a Strong Growth Stock
10:46am, Monday, 21'st Jul 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Repligen to Report Second Quarter 2025 Financial Results
07:30am, Thursday, 17'th Jul 2025
Webcast and Conference Call to Be Held Tuesday, July 29, 2025, at 8:30 a.m. ET Webcast and Conference Call to Be Held Tuesday, July 29, 2025, at 8:30 a.m. ET
908 Devices Appoints Christopher D. Brown to its Board of Directors
08:00am, Monday, 16'th Jun 2025
BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that it has appointed Christopher D. Brown, PhD, Vice President,
Why Is Repligen (RGEN) Down 12.2% Since Last Earnings Report?
12:36pm, Thursday, 29'th May 2025
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?
Repligen Announces Publication of the Company's 2024 Corporate Sustainability Report
07:30am, Tuesday, 27'th May 2025
WALTHAM, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of
Repligen Corporation to Present at Upcoming May Investor Conferences
07:30am, Wednesday, 07'th May 2025
WALTHAM, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participati
QGEN or RGEN: Which Is the Better Value Stock Right Now?
12:41pm, Friday, 02'nd May 2025
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Qiagen (QGEN) and Repligen (RGEN). But which of these two stocks is more attractive to v
Repligen's Q1 Earnings Beat Estimates, Revenues Surge Y/Y
10:10am, Wednesday, 30'th Apr 2025
RGEN reports better-than-expected first-quarter results. The company increases its total revenue (on a reported basis) guidance for 2025.
Repligen Corporation (RGEN) Q1 2025 Earnings Call Transcript
12:58pm, Tuesday, 29'th Apr 2025
Repligen Corporation (NASDAQ:RGEN ) Q1 2025 Earnings Conference Call April 29, 2025 8:30 AM ET Company Participants Jacob Johnson - VP, IR Olivier Loeillot - President, CEO & Director Jason Garland -
Repligen (RGEN) Tops Q1 Earnings and Revenue Estimates
09:45am, Tuesday, 29'th Apr 2025
Repligen (RGEN) came out with quarterly earnings of $0.39 per share, beating the Zacks Consensus Estimate of $0.35 per share. This compares to earnings of $0.28 per share a year ago.
Repligen Reports First Quarter 2025 Financial Results
07:30am, Tuesday, 29'th Apr 2025
WALTHAM, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its
Will Repligen (RGEN) Beat Estimates Again in Its Next Earnings Report?
01:15pm, Wednesday, 23'rd Apr 2025
Repligen (RGEN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Repligen (RGEN) Reports Next Week: Wall Street Expects Earnings Growth
11:05am, Tuesday, 22'nd Apr 2025
Repligen (RGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
